FGFR1 (V561M)
Sign in to save this workspaceFGFR1 · Variant type: point · HGVS: p.V561M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 94.5% | 5.5% | 82.96 |
| 2 | Ponatinib | 84.8% | 15.3% | 78.23 |
| 3 | Pralsetinib | 78.5% | 21.6% | 93.43 |
| 4 | Defactinib | 72.0% | 27.9% | 92.68 |
| 5 | Futibatinib | 69.4% | 30.6% | 98.48 |
| 6 | Fedratinib | 68.6% | 31.4% | 96.21 |
| 7 | Sunitinib | 65.8% | 34.2% | 91.73 |
| 8 | Infigratinib | 58.5% | 41.5% | 98.24 |
| 9 | Entrectinib | 57.0% | 43.0% | 93.69 |
| 10 | Pacritinib | 55.7% | 44.3% | 88.64 |
| 11 | Upadacitinib | 54.4% | 45.6% | 97.98 |
| 12 | Repotrectinib | 50.7% | 49.3% | 84.21 |
| 13 | Erdafitinib | 48.4% | 51.6% | 95.71 |
| 14 | Pemigatinib | 41.9% | 58.1% | 98.23 |
| 15 | Selpercatinib | 41.7% | 58.3% | 96.72 |
| 16 | Nintedanib | 39.8% | 60.2% | 90.23 |
| 17 | Alpelisib | 38.2% | 61.8% | 97.22 |
| 18 | Tenalisib | 34.0% | 66.0% | 97.98 |
| 19 | Axitinib | 30.8% | 69.2% | 93.23 |
| 20 | Neratinib | 22.0% | 78.0% | 93.18 |
| 21 | Ripretinib | 20.8% | 79.2% | 92.95 |
| 22 | Fostamatinib | 20.3% | 79.7% | 96.74 |
| 23 | Lenvatinib | 17.9% | 82.1% | 97.74 |
| 24 | Crizotinib | 17.4% | 82.6% | 91.39 |
| 25 | Avapritinib | 16.8% | 83.2% | 97.73 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 94.5% | 94.7% | -0.1% |
| Ponatinib | 84.8% | 98.9% | -14.2% |
| Pralsetinib | 78.5% | 93.2% | -14.7% |
| Defactinib | 72.0% | — | — |
| Futibatinib | 69.4% | 99.0% | -29.6% |
| Fedratinib | 68.6% | 72.8% | -4.2% |
| Sunitinib | 65.8% | — | — |
| Infigratinib | 58.5% | 99.2% | -40.7% |
| Entrectinib | 57.0% | 76.8% | -19.9% |
| Pacritinib | 55.7% | — | — |
| Upadacitinib | 54.4% | — | — |
| Repotrectinib | 50.7% | — | — |
| Erdafitinib | 48.4% | 99.0% | -50.5% |
| Pemigatinib | 41.9% | 99.9% | -58.0% |
| Selpercatinib | 41.7% | 87.4% | -45.7% |
| Nintedanib | 39.8% | 95.9% | -56.1% |
| Alpelisib | 38.2% | 98.7% | -60.5% |
| Tenalisib | 34.0% | 93.2% | -59.2% |
| Axitinib | 30.8% | 94.9% | -64.0% |
| Neratinib | 22.0% | — | — |
| Ripretinib | 20.8% | 86.5% | -65.7% |
| Fostamatinib | 20.3% | — | — |
| Lenvatinib | 17.9% | 85.5% | -67.6% |
| Crizotinib | 17.4% | — | — |
| Avapritinib | 16.8% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| glioma_central_nervous_system | Brain/CNS | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.3ms